Protagenic Therapeutics, Inc.
PTIX
$0.218
-$0.0001-0.05%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -142.46% | 60.11% | 6.83% | -2.87% | -20.02% |
| Total Depreciation and Amortization | 0.00% | 0.00% | 0.00% | -52.63% | 1,800.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -60.00% |
| Total Other Non-Cash Items | -34.11% | 17.06% | 32.28% | -75.92% | 297.57% |
| Change in Net Operating Assets | 189.64% | 211.82% | -57.47% | 38.22% | -132.40% |
| Cash from Operations | -341.46% | 88.03% | 6.47% | -44.98% | -74.50% |
| Capital Expenditure | -- | -- | -- | -- | -68.46% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -100.00% | 33.01% | -49.29% | 266.90% |
| Cash from Investing | -- | -100.00% | 33.01% | -47.20% | 285.66% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 405.39% | 612.36% | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 405.39% | 612.36% | -- | -- | -- |
| Foreign Exchange rate Adjustments | 500.00% | -150.00% | 0.00% | -77.78% | 181.82% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 496.57% | 41.38% | 120.35% | -140.20% | 1,816.49% |